ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 07 December 8:00AM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
mindful1 mindful1 3 minutes ago
Dear OldAimGuy, JoeForkeyBolo, The Grabber, and many others.
Thanks for sharing your insights and experiences using the AIM system. Are the parameters in the book i.e. 10% buy safe, 10% sell safe, and order size of 10% stock value optimal? Using 5% order size will result in many more trad
PonderosaPack PonderosaPack 3 minutes ago
I read through that Patent. I'm a mechanical engineer - and this technology is just eons above my understanding. I took some electrical engineering classes - and did pretty well with it all - this stuff is so far out there. Mind blowing stuff - just mind blowing. I wonder if the US patent dep
IONQ
Toronto_Trader Toronto_Trader 3 minutes ago
It is interesting that aside from the 30 mil shares added about 5 weeks ago, the price slid down considerably for no other reason than because of impatient shareholders.

$BCDS
BCDS
familyof5 familyof5 3 minutes ago
AFFU November 2024 Market Maker Report


AFFU
Affluence Corporation Common Stock


GTSM
GTS SECURITIES LLC
114,151,118
1
39.7%


OTCN
OTC LINK NQB IDQS
65,511,666 ***&#x
AFFU
cojoboy cojoboy 4 minutes ago
Gotta love these "people" that claim to buy @MB x's..smh..wish I was that good..??..lol.🤔🤔🤔🤔
RDAR
Bigfootbud Bigfootbud 4 minutes ago
1 Samuel 12:24 Only fear the Lord, and serve Him in truth with all your heart; for consider what great things He has done for you.
boston745 boston745 4 minutes ago
Do you have anything else that you can criticize other than reverse splits which required manipulation of the stock to create? I certainly could and have talked about some things that are very questionable. Something else so call bear here will not even do, which is how you know they are part of th
SINT
Gatorca Gatorca 5 minutes ago
Buying a little More Mon...Will use a little Holiday bonus...
EMGE
Bigfootbud Bigfootbud 5 minutes ago
I tell you that one greater than the temple is here.
—Matthew 12:6
BIOCHEMUP BIOCHEMUP 5 minutes ago
 Check QBTS too by the way 
QBTS
JD400 JD400 6 minutes ago
Rob McEwen - These Commodities Will Be On Everyone's Radar

Dec 1, 2024 #Wealthprotection #Singapore #Wealthpreservation
Rob McEwen from McEwen Mining joins Patrick Vierra in a chat about the economy, precious metals, the health of the miners, and the challenges they face. Re
MUX
arizona1 arizona1 6 minutes ago
https://scontent-lax3-1.xx.fbcdn.net/v/t39.30808-6/469465108_8753584941386764_6698357348068028015_n.jpg?stp=dst-jpg_p526x296_tt6&_nc_cat=108&ccb=1-7&_nc_sid=127cfc&_nc_ohc=rk5P-qEm-R8Q7kNvgG_qOv8&_nc_zt=23&_nc_ht=scontent-lax3-1.xx&_nc_gid=ALeq_OzuqZZDAeIwbR7b94N&oh=00_AYD4hoVSbygUIzE4w0e4VNqkYwYMu-
EternalPatience EternalPatience 6 minutes ago
Could you please elaborate on How foolish you felt when you typed those 3 letters ?  LOL..   Would have loved to see your face  
FNMA
Jack_of_All_Trades Jack_of_All_Trades 7 minutes ago
RDAR another awesome close on pending mega merger!!!
RDAR
Toronto_Trader Toronto_Trader 7 minutes ago
I have multiple pennies in mind if the company does this correctly. I could afford to buy up 1/2 of the unrestricted shares myself so this will move fast when it begins to break out. I’ll just hold my 10 mil for now.

$BCDS
BCDS
peanutz peanutz 7 minutes ago
My guess is the 25 range by Christmas
SOUN
WebSlinger WebSlinger 9 minutes ago
Super Micro Computer said it has been granted an exceptional extension from Nasdaq that would allow it to file its latest annual report through Feb. 25, 2025 .

The server maker that saw its business take off with the artificial-intelligence boom on Friday said it currently expects t
SMCI
Zorax Zorax 9 minutes ago
Centene and CVS, which owns Aetna, have left executive biographies intact but removed headshots of their officers. Corporate governance pages for Cigna, Humana and Molina remained unchanged as of press time.

The author of the piece should have thought a bit about that descriptor.
CVS
BIOCHEMUP BIOCHEMUP 9 minutes ago
Where you see this going? I have a sell order at $17.
SOUN
Jack_of_All_Trades Jack_of_All_Trades 9 minutes ago
RDAR another awesome close on pending mega merger!!!
RDAR
JD400 JD400 10 minutes ago
Rob McEwen - These Commodities Will Be On Everyone's Radar

Dec 1, 2024 #Wealthprotection #Singapore #Wealthpreservation
Rob McEwen from McEwen Mining joins Patrick Vierra in a chat about the economy, precious metals, the health of the miners, and the challenges they face. Re
peanutz peanutz 10 minutes ago
This breaks 20 next week I believe. Monster in the making .
SOUN